First full-length structure of GLP-1 receptor bound to peptide agonist

June 1, 2017, Heptares Therapeutics

Heptares Therapeutics has published the first high-resolution X-ray crystal structure of the full-length glucagon-like peptide-1 (GLP-1) receptor bound to a peptide agonist.

The findings, published in Nature, provide insight to the molecular mechanism of action of GLP-1 peptides and their interactions with the receptor. Importantly, this pioneering research further validates and enables the application of structure-based methods to the design of optimised peptide therapeutics and small molecules targeting the GLP-1 receptor, and related G protein-coupled (GPCRs), for treating a range of diseases.

GLP-1 is an important peptide hormone that regulates glucose homeostasis through control of insulin release from the pancreas. Activating the GLP-1 receptor is one of the most important and highly validated mechanisms for treating Type 2 diabetes, and awareness is increasing about the potential of this target in treating other , as well as cardiovascular and neurological diseases. A number of GLP-1 peptide agonists, with improved stability and duration of action compared to native GLP-1, are already approved for treating Type 2 diabetes, including exenatide (Byetta/Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Lyxumia), albiglutide (Tanzeum) and dulaglutide (Trulicity).

Fiona Marshall, chief scientific officer of Heptares and Sosei, said: "The findings from this research at Heptares are ground-breaking and very exciting: they unveil a remarkably complex network of interactions between GLP-1 peptide ligands and the receptor that explain why it has been so difficult to mimic this effect with a small molecule. Understanding these interactions at a molecular level may be the breakthrough that enables the design of small molecule drugs, as well as optimised therapeutic , targeting not only the GLP-1 receptor but also other closely related GPCR targets implicated in many diseases."

The GLP-1 receptor is a member of the Class B secretin group of GPCRs, a family of structurally similar receptors for peptide hormones such as GLP-1, glucagon, corticotropin-releasing factor (CRF), calcitonin and parathyroid peptide hormone. Class B GPCRs include many therapeutic targets for cardiovascular diseases, metabolic diseases, bone diseases and migraine, but despite strong clinical validation, structural information is limited.

Explore further: Scientists make receptor discoveries that pave the way for new drugs to treat metabolic diseases

More information: Ali Jazayeri et al. Crystal structure of the GLP-1 receptor bound to a peptide agonist, Nature (2017). DOI: 10.1038/nature22800

Related Stories

Cyclic opioid peptides

July 13, 2016

Peptide based drug candidates are being discovered at an increasingly rapid pace as therapeutics for many diseases and pain management. . For decades the opioid receptors have been an attractive therapeutic target for pain ...

Recommended for you

New theory shows how strain makes for better catalysts

April 20, 2018

Brown University researchers have developed a new theory to explain why stretching or compressing metal catalysts can make them perform better. The theory, described in the journal Nature Catalysis, could open new design ...

Machine-learning software predicts behavior of bacteria

April 19, 2018

In a first for machine-learning algorithms, a new piece of software developed at Caltech can predict behavior of bacteria by reading the content of a gene. The breakthrough could have significant implications for our understanding ...

Spider silk key to new bone-fixing composite

April 19, 2018

UConn researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

GLUT5 fluorescent probe fingerprints cancer cells

April 19, 2018

Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.